Vertex Pharmaceuticals Inc. (VRTX) Buy, Sell… — Stockchase

Daily Stock Opinions and Ratings

Vertex Pharmaceuticals Inc. (VRTX)

516.44

-9.29 (1.77%)

as of Aug 13, 2026, 8:00:00 pm Market Open.

78 watching

Investor Insights

Aug 14, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Vertex Pharmaceuticals Inc. (VRTX-Q) has recently emerged from a period of dormancy and is receiving favorable attention in the market. The company has a stronghold in the cystic fibrosis treatment space, which is proving to be a significant contributor to its growth. In addition to its success within its core market, Vertex is expanding into other therapeutic areas, showcasing its potential for broader applications and revenue streams. Experts indicate that the company's current trajectory positions it favorably within the pharmaceutical sector, making it an attractive option for investors. Overall, Vertex is seen as a promising player poised to capitalize on both its existing assets and exploratory ventures.

Consensus

Positive

Valuation

Undervalued

Similar

ALNY,ALNY

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 21%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $230) to $245.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 16.4%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with VRTX has achieved its $258 objective. To remain disciplined, we recommend covering half the position here and trailing up the stop (from $220) to $230.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 04/22, Up 21.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX is progressing well. We now recommend trailing up the stop (from $200) to $220.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly We again reiterate this long known developer of treatment for cystic fibrosis as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases such as Type I diabetes and muscular dystrophy. Recently reported earnings beat analyst expectations by 30% and the company maintains a ROE of 31%. We also like how the company has continued to increase cash reserves, while buying back stock. We recommend trailing up the stop (from $185) to $200, looking to achieve $258 -- upside potential over 16%. Yield 0% (Analysts’ price target is $257.41)

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This long known developer of treatment for cystic fibrosis is again reiterated as a TOP PICK. Its diversified portfolio of therapeutic drugs continues to pursue treatment in other major diseases and has recently announced success with an oral kidney treatment drug. We like how the company has continued to increase cash reserves, while paying down debt and buying back stock. We recommend trailing up the stop (from $165) to $185, looking to achieve $255 -- upside potential over 22%. Yield 0% (Analysts’ price target is $254.19)

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly VRTX is a previous Top Pick that had two setbacks that caused us to recommend moving to the sidelines. However, its diversified portfolio of therapeutic drugs continues to play a leading role in the potential treatment of cystic fibrosis worldwide. It trades at 17x earning compared to peers at 43x. It has been adding cash reserves that are now estimated to exceed $8 billion. We would buy this with a stop loss at $165, looking to achieve $275 -- upside over 46%. Yield 0% (Analysts’ price target is $275.86)

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jan 19/21, Down 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VRTX has triggered its stop at $200. We recommend covering the position at this time. We will look for better opportunities elsewhere.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly VRTX is a pharmaceutical company that is world renowned in its treatment for cystic fibrosis. The company is estimated to have increased its cash position by almost $2 billion, leaving it plenty in the tank to develop other life changing drugs likes ones being developed for sickle cell disease and AAT deficiency. We would buy this with a stop-loss at $200, looking to achieve $290 -- over 25% upside potential. Yield 0% (Analysts’ price target is $289.66)

PAST TOP PICK

(A Top Pick Nov 14/19, Up 16%) This shot up from its base around $175 starting last October. No longer owns it. Pharma is fairly predictable, buy may be kicked around by US politicians during the campaign. He suggests entering the pharma space now.

TOP PICK

They specialize in serious diseases. It is volatile. You could just own the XBB-T. He thinks our life span is going to expand significantly and these guys are going to be part of it. (Analysts’ price target is $226.45)

Showing 31 to 40 of 40 entries

Previous Page

«
‹
1
2
3
›
»

Popular Articles

Most Recent Experts

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Chris Blumas

at Raymond James Investment Counsel Ltd.

Shannon Saccocia, CIO, Boston Private

Boston Private

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

© 2000 - 2026 Stockchase Inc.